OJRD

Pharnext: Pharnext Reports Full Year 2021 Financial Results and Recent Business Updates

Retrieved on: 
Monday, April 25, 2022
Patient, CMT, Degenerative disease, Patent, Board, Abhijit, Awareness, OJRD, OCA, CET, Life, Program, Mission statement, Regulatory affairs, EUR, Director, Company, Orphanet Journal of Rare Diseases, Neurodegeneration, CMC, Regulatory News Service, IFRS, Safety, Absa Bank Kenya Plc, Income, Certification, Disease, Therapy, Head, Pharmaceutical industry

Pharnext initiated the pivotal Phase III clinical study of PXT3003, the PREMIER trial.

Key Points: 
  • Pharnext initiated the pivotal Phase III clinical study of PXT3003, the PREMIER trial.
  • The first patient was enrolled in the PREMIER trial in the US in March 2021 and in Europe in July 2021.
  • Pharnext is also conducting the open-label extension of the PLEO-CMT study, the PLEO-CMT-FU trial.
  • Over 2021, Pharnext has maintained its partnerships with CMT patient advocacy groups in the US and Europe.

Pharnext: Data from First Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A, the PLEO-CMT Trial, Published in the Orphanet Journal of Rare Diseases

Retrieved on: 
Monday, October 18, 2021
Human, Schwann cell, Safety, AMF, Baclofen, Disease, FDA, Sorbitol, Lead, Phase II, Orphanet Journal of Rare Diseases, CET, Charcot–Marie–Tooth disease, Patient, Mission statement, Intention, Doctor of Philosophy, URD, ClinicalTrials.gov, Life, Neurodegeneration, HD, Company, Prospectus, MD, Genomics, Drug discovery, Degenerative disease, EMA, Occupational therapy, Genta (company), Trial of the century, ISIN, OJRD, Therapy, Intelligence, CMT, Artificial intelligence, Running, Naltrexone, PMP22, III, Walking, Wheelchair, Prevalence, LD, Alzheimer's disease, Regulatory News Service, High, ALS, Muscle atrophy, Muscle, Pharmaceutical industry, Security (finance), CHARCOT-MARIE-TOOTH DISEASE TYPE 1A ('CMT1A'), PXT3003, THE PLEO-CMT TRIAL, THE PLEO-CMT-FU TRIAL, THE PREMIER TRIAL, PHARNEXT

Pharnext: Data from First Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A, the PLEO-CMT Trial, Published in the Orphanet Journal of Rare Diseases

Key Points: 
  • Pharnext: Data from First Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A, the PLEO-CMT Trial, Published in the Orphanet Journal of Rare Diseases
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • This extension study is still ongoing, and 130 patients are still receiving treatment with high-dose PXT3003.
  • The second international, randomized, double-blind, two-arm placebo-controlled Phase III study of PXT3003, the PREMIER trial, was initiated in March 2021 in the U.S.
  • PXT3003 has shown promising and consistent results across preclinical and clinical studies in Phase II and Phase III (PLEO-CMT and PLEO-CMT-FU).